Your browser doesn't support javascript.
Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals.
Barros-Martins, Joana; Hammerschmidt, Swantje I; Morillas Ramos, Gema; Cossmann, Anne; Hetzel, Laura; Odak, Ivan; Köhler, Miriam; Stankov, Metodi V; Ritter, Christiane; Friedrichsen, Michaela; Ravens, Inga; Schimrock, Anja; Ristenpart, Jasmin; Janssen, Anika; Willenzon, Stefanie; Bernhardt, Günter; Lichtinghagen, Ralf; Bosnjak, Berislav; Behrens, Georg M N; Förster, Reinhold.
  • Barros-Martins J; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Hammerschmidt SI; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Morillas Ramos G; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Cossmann A; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Hetzel L; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Odak I; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Köhler M; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Stankov MV; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Ritter C; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Friedrichsen M; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Ravens I; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Schimrock A; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Ristenpart J; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Janssen A; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Willenzon S; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Bernhardt G; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Lichtinghagen R; Department of Clinical Chemistry, Hannover Medical School, Hannover, Germany.
  • Bosnjak B; Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Behrens GMN; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Förster R; German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.
Front Immunol ; 14: 1166589, 2023.
Article in English | MEDLINE | ID: covidwho-2321884
ABSTRACT
Since early 2022, various Omicron variants have dominated the SARS-CoV-2 pandemic in most countries. All Omicron variants are B-cell immune escape variants, and antibodies induced by first-generation COVID-19 vaccines or by infection with earlier SARS-CoV-2 variants largely fail to protect individuals from Omicron infection. In the present study, we investigated the effect of Omicron infections in triple-vaccinated and in antigen-naive individuals. We show that Omicron breakthrough infections occurring 2-3.5 months after the third vaccination restore B-cell and T-cell immune responses to levels similar to or higher than those measured 14 days after the third vaccination, including the induction of Omicron-neutralizing antibodies. Antibody responses in breakthrough infection derived mostly from cross-reacting B cells, initially induced by vaccination, whereas Omicron infections in antigen-naive individuals primarily generated B cells binding to the Omicron but not the Wuhan spike protein. Although antigen-naive individuals mounted considerable T-cell responses after infection, B-cell responses were low, and neutralizing antibodies were frequently below the limit of detection. In summary, the detection of Omicron-associated B-cell responses in primed and in antigen-naive individuals supports the application of Omicron-adapted COVID-19 vaccines, but calls into question their suitability if they also contain/encode antigens of the original Wuhan virus.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2023 Document Type: Article Affiliation country: Fimmu.2023.1166589

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2023 Document Type: Article Affiliation country: Fimmu.2023.1166589